AbbVieNYSE: ABBV
AbbVie (NYSE: ABBV) is a global biopharmaceutical company and one of the first large pharma entrants in next-generation psychedelic medicine. In May 2024, AbbVie partnered with Gilgamesh Pharmaceuticals ($65M upfront, up to $1.95B in milestones) to develop novel CNS therapies including neuroplastogens. In August 2025, AbbVie acquired bretisilocin (GM-2505) — a short-acting IV serotonergic psychedelic (DMT analog) from Gilgamesh — for up to $1.2B, marking one of the largest psychedelic drug deals in history. Bretisilocin's Phase 2a data showed a -21.6 point MADRS reduction at Day 14 (p=0.003). AbbVie continues to collaborate with Gilgamesh Pharma Inc. (Gilgamesh's spin-off) on earlier-stage programmes.
Drug Pipeline
2Bretisilocin (GM-2505)
DMTMajor depressive disorder (MDD). IV bretisilocin (5F-MET), a short-acting DMT analog with 60–90 min psychedelic duration. Phase 2a (NCT06236880): single 10 mg dose showed -21.6 MADRS at Day 14 vs -12.1 for 1 mg active comparator (p=0.003). Well tolerated, no serious adverse events. Acquired from Gilgamesh Pharmaceuticals by AbbVie for up to $1.2B (completed Oct 2025). Phase 3 planning underway.
GM-5022
MDD and anxiety. Oral non-hallucinogenic neuroplastogen in IND-enabling studies; developed by Gilgamesh Pharma Inc. (spin-off) under ongoing AbbVie collaboration. Targets rapid, durable neuroplasticity without psychoactive effects, enabling potential outpatient use.
Quick Facts
- Type
- Big Pharma
- Ticker
- NYSE: ABBV
- Lead Stage
- Phase II
- HQ
- 1 North Waukegan Road, North Chicago, IL 60064, USA, United States
- Website
- Visit